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New Technologies, Human-Microbe Interactions, and the Search for Previously 
Unrecognized Pathogens 
David A. Relman Departments of Microbiology and Immunology and of Medicine, 
Stanford University, Stanford, and Department of Veterans Affairs 
Palo Alto Health Care System, Palo Alto, California 
Evidence suggests that a significant number of clinically important microbial pathogens 
remain unrecognized. Observations from the natural world, from patterns of disease in human 
populations, from the bedside, and from the clinical laboratory all contribute to this body of 
evidence. A variety of acute and chronic neurologic syndromes illustrate this point; despite 
features of infection, most cases of aseptic meningitis, encephalitis, and cerebral vasculitis 
cannot be assigned a microbiologic diagnosis. The development and clinical application of 
molecular methods have led to the discovery of novel members of the endogenous normal 
flora as well as putative disease agents. Current challenges include the establishment of criteria 
for disease causation and further characterization of the human microbiome during states of 
health. These challenges and the goal of understanding microbial contributions to inflam- 
matory disease may be addressed effectively through the thoughtful integration of modern 
technologies and clinical insight. 
Microbial Diversity and the Limitations of Cultivation 
Methods 
About 25 years ago, explorations of the natural microbial 
world turned toward extreme environments and exploited the 
use of newly described molecular approaches for phylogenetic 
analysis and classification. Recovery of sequence-based signa- 
tures of life directly from these environments confirmed revo- 
lutionary proposals for three aboriginal lines of descent [1] and 
led to the realization that nearly all microbial life is resistant 
to cultivation in the laboratory. With increasing reliance on 
molecular methods in environmental microbiology, a picture of 
microbial diversity emerged that currently includes as many as 
40 major divisions of bacteria, a broad and cosmopolitan do- 
main of life known as the Archaea, and an intertwined early 
history of endosymbiotic prokaryotes, eukaryotic protists, and 
lateral gene transfer events [2, 3]. 
The inadequacies of available cultivation techniques are re- 
flected by the fact that at least 9007o of all known cultivated 
bacterial species lie within just 4 of the 40 divisions, even though 
many of the other divisions are equally diverse and well pop- 
ulated [3]. That 6507o of all published microbiologic research 
over a 6-year period was related to just 8 bacterial genera dra- 
matically illustrates our strong bias toward bacteria that are 
amenable to cultivation [4]. Given this recent history, it is of 
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concern that clinical microbiology continues to rely heavily 
upon cultivation-based methods, but perhaps not surprising. 
The internal environmental conditions of the human body are 
seemingly more familiar to us than those that are external, the 
internal niches have been the subjects of frequent study, and 
there is certainly no dearth of known microbial pathogens. But 
we should not be so complacent. 
When traditional diagnostic methods are rigorously applied 
to syndromes of suspected infectious etiology, such as pneu- 
monia, encephalitis, lymphocyte-predominant meningitis, per- 
icarditis, acute diarrhea, and sepsis, only a minority of cases 
can be explained microbiologically. In addition, a long list of 
chronic inflammatory diseases with features of infection re- 
mains poorly understood. Thus, it seems fair to speculate that 
the distribution of known pathogens in only 7 bacterial divi- 
sions and the absence of any known pathogens within the do- 
main Archaea may represent an imperfect understanding of the 
true diversity of microbes capable of causing human disease. 
Molecular Approaches for Microbial Pathogen Detection 
and Identification: Seeking Signatures 
In an effort to avoid reliance on cultivation and to establish 
alternative and complementary approaches, one might view the 
goal in microbial detection and pathogen discovery as a quest 
to identify molecular signatures of infection. These signatures 
must be reliable for identifying a microorganism and for es- 
tablishing the relationships of a previously uncharacterized or- 
ganism with those previously characterized. Molecular signa- 
tures can be based directly on the features of the microbe itself 
or upon the features of the host response to a pathogen. There 
are a variety of methods and techniques with which to acquire 
each of these two types of signatures [5] (see figure 1). 
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Pathogen as source of signature 
?broad range PCR 
?microbial/viral survey "phyloarray" 
?subtractive/comparative methods 
* representational difference analysis 
* differential display 
?expression or phage display library screening 
(using host antisera or T-cells) 
?small molecule or protein detection (e.g. with mass 
spectroscopy) 
Host as source of signature 
?host genome-wide transcript profiling (e.g. using 
microarrays) 
?host protein profiling (e.g. using microarrays, or mass 
spectroscopy) 
Figure 1. Pathogen discovery by seeking molecular signatures. 
PCR, polymerase chain reaction. Modified from figure 4 in [6]. 
Genomic sequence is the most frequently used "currency" in 
the identification of microbial signatures, and broad-range (or 
consensus) polymerase chain reaction (PCR) is the most prac- 
tical tool for generating this currency [5]. Furthermore, rDNA 
is among the most useful genome sequences from which or- 
ganismal ancestry and interrelationships can be reliably inferred 
and pathogen discovery approaches designed [7, 8]. With recent 
improvements in the speed at which primary genome sequence 
can be acquired and analyzed, other detection or screening 
formats may become widely available and additional regions 
of microbial (and viral) genomes more commonly targeted. For 
example, high-density microarrays of oligonucleotides or am- 
plified DNA products can be designed to screen complex pools 
of microbial nucleic acid for specific agents in a massively par- 
allel and efficient manner [9]. This technical platform obviates 
the need to clone and sequence large numbers of variant mi- 
crobial molecules. This is particularly relevant to the analysis 
of clinical specimens with a significant burden of "background" 
microorganisms (see further discussion below) and facilitates 
more sophisticated uses of pattern recognition analysis as a 
tool for microbial signature identification. 
There are at least two alternative kinds of approaches for 
detecting diagnostic signatures of microbial origin that incor- 
porate features to help discriminate between signal and noise. 
The first relies on differential analysis of microbial sequences 
in specimens from host sites that are involved and uninvolved 
in disease. Differential display is a screen for differences in 
sequence diversity and abundance between involved and un- 
involved sites; representational difference analysis (RDA) in 
essence selects for sequences of differential abundance by use 
of PCR [10, 11]. Both share the disadvantage that the sequences 
of differential abundance that are revealed by these methods 
may not be useful markers for microbial identification. A study 
of Crohn's disease illustrates this problem [12]. The investiga- 
tors applied RDA to specimens from involved and uninvolved 
segments of intestinal tissue from a patient with Crohn's disease 
and obtained random fragments of bacterial genome. Although 
the encoded molecules may be relevant to the disease process 
[13], the identity of the source organism(s) remains unknown. 
The second kind of alternative approach relies upon the host 
immune response to identify sequences that may originate from 
a putative pathogen. These techniques include screening of ex- 
pression or phage display peptide libraries with patient antisera 
or reactive T cells [14]. 
Despite a preponderance of efforts to discover and detect 
microbes by targeting them directly, the nature of the host re- 
sponse to infection offers attractive features for pathogen de- 
tection and classification that are unique and complementary. 
In theory, the host response can serve as a source of microbial 
signatures that are by definition clinically relevant?that is, it 
may provide signatures that distinguish between infection and 
disease. The logic behind this speculation lies in the fact that 
regulation of gene expression is one mechanism at the basis of 
host pathology. Gene expression patterns should reflect the suc- 
cess or failure of microbial virulence strategies and of host 
defenses. This type of signature is intimately connected to clin- 
ical outcome and may therefore provide prognostic value. Fi- 
nally, signatures based on host response do not require the 
presence of the putative pathogen in a clinical specimen. 
Exploring the Human Microbiome in Health 
and Disease 
Molecular technique surveys of the microbial communities 
associated with humans during states of health have belatedly 
been initiated. These surveys are important for a number of 
reasons. In addition to the numerous but poorly characterized 
beneficial effects of the endogenous microflora on human 
health, a proper understanding of community membership, rel- 
ative abundance, and variations therein will be critical for rec- 
ognizing potential pathogens and patterns that are predictive 
of disease. 
The subgingival crevice in the mouth is one of the more 
intensively studied and better-understood colonized sites of the 
human body. Molecular surveys that used broad-range rDNA 
PCR suggest that 5007o-600Zo of the bacteria present at this site 
are distinct from all of those previously described at the tax- 
onomic level of species?albeit, a term that is loosely defined 
[15,16]. Some of these bacteria are not assigned to the dominant 
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four divisions, Actinobacteria, Firmicutes, Bacteroidetes, and 
Proteobacteria, and belong to divisions such as TM7 and OP11 
that have not been previously discussed by clinicians or clinical 
microbiologists, probably because they contain no known cul- 
tivated members. 
Molecular surveys of the endogenous flora of the human 
intestinal tract have only just begun. Although the clinical sig- 
nificance of the newly discovered community membership is 
not established, it is clear that human endogenous microflora 
play an important role in a variety of important disease states 
involving the skin and mucosal tissues. The relatively recent 
discovery of Helicobacter pylori as a common persistent human 
colonizer and a cause of peptic ulcer disease and gastric ade- 
nocarcinoma in certain subsets of hosts illustrates some of the 
complexities of host-microbe interactions at the mucosal 
boundary [17, 18]. What is not clear, but widely speculated 
about, is the possible role of the endogenous flora in either 
provoking or propagating disease at distant sites, including the 
central nervous system. The proposed associations between vi- 
ral respiratory infections and subsequent flares of multiple scle- 
rosis and between Campylobacter jejuni enterocolitis and Guil- 
lain-Barre syndrome [19] are just two examples. 
As one broad approach to the problem of a poorly under- 
stood endogenous flora, one might consider a second human 
genome project [20]. Such a project would entail a comprehen- 
sive inventory of microbial genes and genomes at the 4 major 
sites of microbial colonization in the human body: mouth, gut, 
vagina, and skin. It would be approached through random 
shotgun sequencing procedures, targeted large-insert clone se- 
quencing, and assessments of intra- and interindividual vari- 
ation by using high-density microarrays. With increasing de- 
grees of population sampling in well-characterized settings and 
with the integration of host genome-wide expression analysis 
[20, 21], major insights into the role of the endogenous flora 
in health and disease will be gained. 
Microbial Signatures: Complications 
Important lessons have been learned in recent years about 
the use and limitations of molecular methods for microbial 
pathogen detection and signature analysis. First, despite the 
expectation that sequences identified as universally conserved 
within a group of organisms are in fact found in all members 
of the group, this assumption is not always justified. As pre- 
viously unrecognized members of a group are revealed, small 
additional degrees of sequence variation are sometimes discov- 
ered. The small subunit rDNA sequences that were originally 
described as universal are now known to be conserved in only 
a subset of cellular life [22]; revised sequence sites have taken 
their place. Second, PCR can exhibit bias and favor certain 
members of a mixed starting pool of molecules. The use of 
multiple broad-range primer pairs or reaction cosolvents may 
avoid a skewed perspective. Third, conserved sequences for use 
in broad-range PCR have not yet been identified and validated 
for all groups of viruses. This limitation most certainly con- 
tributed to the sizeable number of cases that remained unex- 
plained after investigation by the Unexplained Deaths and Crit- 
ical Illnesses Working Group within the CDC's Emerging 
Infections Program [23]. 
One issue of particular importance concerns the complexity 
and widespread distribution of microbial sequence "back- 
ground" or "noise" observed in the analysis of human clinical 
specimens (both experimental and biological). The distribution 
and nature of this sequence background still is not well char- 
acterized. Findings of bacterial rDNA in association with blood 
samples from healthy humans threatens to expand the extent 
of this problem into anatomic compartments that have been 
traditionally viewed as usually sterile [24]. A different perspec- 
tive on this same apparent problem was provided in an analysis 
of expressed sequence tag libraries from human tissues [25, 26]. 
Some of these transcripts that were originally assumed to derive 
from the human genome appear on closer inspection to be of 
microbial origin. Whether some of these molecules were in- 
trinsic to the original specimen or introduced later remains 
unclear, but some are easily attributed to agents that are com- 
mon, persistent, or dormant infectious agents found within 
these human tissues. 
The increasing availability of molecular pathogen discovery 
methods and the ease with which molecular signatures are gen- 
erated create a pressing problem of a different kind. How can 
one build a convincing body of evidence for a causative role 
of the putative pathogen in a disease process when the pathogen 
is identified with molecular signatures and has not been isolated 
or purified? The issues surrounding this problem are familiar 
to epidemiologists and have been addressed during the past 
half century. One can adapt the same concepts to the kinds of 
data and techniques generated by modern approaches to path- 
ogen detection and discovery [27]. 
Among a variety of important steps in building an argument 
for causation, the ability to connect a signature physically to 
the sites of pathology where one most expects to find the pu- 
tative disease agent is one helpful evidentiary component. Fluo- 
rescent in situ hybridization allows correlation of a specific 
sequence with areas of pathology and tissue-based microbial 
structures [28, 29]. This approach also examines signature "dos- 
age" effects. Alternatively, anatomic sites of interest can be 
targeted specifically for signature detection by using laser cap- 
ture microdissection [30, 31]. 
Finally, the problems associated with clinical specimens can 
be substantial and potentially prohibitive as highlighted by re- 
sults of the Unexplained Deaths Project [23, 32]. Clinical spec- 
imens from cases of suspected but unproven infectious etiology 
are often obtained late in the disease course, potentially when 
the putative agent is no longer present. The site from which 
the specimen is obtained may not coincide optimally with the 
expected anatomic distribution of the agent. The quantity of 
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specimen may be insufficient for the expected concentration of 
the agent and a reasonable probability of its presence (as a 
single particle or genome-equivalent) in the specimen. And, in 
the real world of clinical medicine, specimen handling and stor- 
age may introduce exogenous contamination, spurious signals, 
or target degradation. 
Recognition and Classification of Microbial Disease 
Based on Host Gene Expression Patterns 
The limitations of methods for analysis of microbial signa- 
tures and the emergence of technology platforms for rapid 
highly parallel gene expression measurements have facilitated 
a potentially important independent approach for identification 
of microbial disease. The basic question raised is, can one rec- 
ognize and classify clinical (and preclinical) states of infection 
by examining host gene response patterns [9, 33]? This approach 
offers several advantages. First, changes in gene transcript 
abundance occur within minutes of a new exogenous stimulus. 
Second, the complexity and diversity of signal transduction 
mechanisms that impact on human gene expression and the 
complexity of the output (at a genome-wide level) are extensive; 
therefore, discrimination between numerous diverse stimuli 
(e.g., different classes of pathogens) may be discernable. Third, 
a clinical specimen need not contain the exogenous stimulus 
(i.e., the infectious agent). Fourth, the intrinsic nature of the 
host response may be directly informative about clinical rele- 
vance of the stimulus (host-microbe interaction) and the clinical 
outcome. However, at present, the answer to this basic question 
is not available. 
To date the vast majority of work in this area has focused 
on the response of host cells to microbial stimuli in vitro (for 
examples, see [34, 35]). A large body of work predates this more 
recent focus on microbial stimuli and addresses the nature of 
the expression patterns associated with various forms of cancer 
[36-38]. These studies revealed gene expression signatures that 
help distinguish subsets of patients that were not previously 
apparent and that have different responses to treatment and 
different outcomes. As many might have predicted, findings 
from examination of host-microbe encounters in vitro indicate 
the predominance of shared gene expression patterns, suggest- 
ing a stereotyped temporally controlled response to microbes 
in human cells [34]. Gene expression responses exhibit microbial 
dose dependence; yet universal, shared dose-equivalence rela- 
tionships are not apparent. From these early experiments, it 
appears that identification of discriminatory (diagnostic) sig- 
natures may be possible. Furthermore, active virulence-asso- 
ciated mechanisms may provide the basis for specific pathogen 
class recognition. 
The transition to an analysis of humans with and without 
known infectious diseases ex vivo is accompanied by a number 
of interesting but complex questions. What is the most useful 
and practical type of clinical specimen from which to record 
genome-wide expression patterns and discern meaningful in- 
formation about infection? Blood cells are attractive given that 
they circulate, make contact with a wide variety of microen- 
vironments and other cell types, and are easy to obtain. But it 
is unclear how well they might reflect a localized infectious 
process (e.g., in the brain). How much variability occurs within 
and between persons during various states of health and during 
noninfectious stimuli? Must each person serve as his or her own 
control for proper interpretation of infection-associated re- 
sponses? What kinds of host-specific genetic information and 
proclivities are embedded in expression data? These questions 
are currently being explored but will require extensive sampling 
before they can be answered in a comprehensive fashion. 
One of the most intriguing questions is, on what basis do 
humans classify noxious stimuli and, in particular, microbial 
causes of disease? Among the most likely uses and practical 
outcomes of these investigations is the identification of patterns 
that predict disease outcome [36]. Furthermore, expression 
analysis can be used to identify predicted membrane-associated 
and secreted proteins [39]. With this approach, diagnostic and 
prognostic transcript abundance patterns can be converted to 
sets of easily measured proteins in body fluids. 
Summary and Future Directions 
A significant number of human-associated microorganisms 
remain unrecognized or poorly characterized. Some may be 
important triggers or promoting factors in unexplained disease. 
Molecular strategies and genomic approaches will enhance our 
ability to recognize these organisms, discern pathophysiologic 
mechanisms, and develop new interventions. Complex biologic 
signatures and pattern recognition are relevant not only to the 
use of genome-wide expression responses for classification and 
characterization of infectious diseases but also to the analysis 
of the endogenous microbial flora, secreted or exhaled volatile 
small molecules [40, 41], and spectral properties of human cells 
and tissues. Work of this type will require an intimate collab- 
oration of experts in multiple disciplines plus shrewd clinical 
insight. Technology cannot substitute for a holistic understand- 
ing of biologic systems but exciting clinical investigation will 
be greatly accelerated by new and emerging technologies. 
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